Results 141 to 150 of about 4,268 (199)

Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.

JAMA Netw Open
Koh SHE, Huang W, Hall EW, Jones J, Zang X, Yarbrough CR, Corbin-Gutierrez EE, Sullivan PS, Siegler AJ.   +8 more
europepmc   +1 more source

The safety of cabotegravir in pregnancy: a systematic review and meta-analysis. [PDF]

BMC Infect Dis
Jasper A, Fourie W, Chetty S.
europepmc   +1 more source

Correction to: Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. [PDF]

Open Forum Infect Dis
europepmc   +1 more source

[Early virological failure with long-acting cabotegravir/rilpivirine: description of two cases]. [PDF]

Rev Esp Quimioter
Pena-López MJ, Torres-Martel EG, Santana-Baez S, Bosch-Guerra X.   +3 more
europepmc   +1 more source

The "Porto Alegre HIV Charter": Confronting the HIV epidemic in Rio Grande do Sul, Southern Brazil. [PDF]

Braz J Infect Dis
Vieceli T, Riche CVW, Buffon VR, Hernandes CP, Falci DR, Junqueira G, Ikeda ML, Volkweis MR, Diaz RS, Pasqualotto AC, Kliemann DA.   +10 more
europepmc   +1 more source

Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic. [PDF]

J Antimicrob Chemother
Liegeon G, Friedman E, Kaperak C, Djuricich P, Dawdani A, Plotkin S, Schmitt J, Hazra A, Christopoulos KA, Schneider JA, McNulty MC.   +10 more
europepmc   +1 more source